Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 3
2017 5
2018 9
2019 12
2020 8
2021 14
2022 9
2023 4
2024 9
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

67 results

Results by year

Filters applied: . Clear all
Page 1
Reply to Ugo De Giorgi, Vincenza Conteduca, and Emanuela Scarpi's Letter to the Editor re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Eur Urol 2017;71:680-7.
Del Re M, Biasco E, Crucitta S, Derosa L, Rofi E, Orlandini C, Miccoli M, Galli L, Falcone A, Jenster GW, van Schaik RH, Danesi R. Del Re M, et al. Among authors: crucitta s. Eur Urol. 2018 Jan;73(1):e11-e12. doi: 10.1016/j.eururo.2017.07.034. Epub 2017 Aug 9. Eur Urol. 2018. PMID: 28801127 No abstract available.
Pharmacological Basis of Breast Cancer Resistance to Therapies - An Overview.
Crucitta S, Cucchiara F, Sciandra F, Cerbioni A, Diodati L, Rafaniello C, Capuano A, Fontana A, Fogli S, Danesi R, Re MD. Crucitta S, et al. Anticancer Agents Med Chem. 2022;22(4):760-774. doi: 10.2174/1871520621666210804100547. Anticancer Agents Med Chem. 2022. PMID: 34348634 Review.
Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer.
Maroni G, Bassal MA, Krishnan I, Fhu CW, Savova V, Zilionis R, Maymi VA, Pandell N, Csizmadia E, Zhang J, Storti B, Castaño J, Panella R, Li J, Gustafson CE, Fox S, Levy RD, Meyerovitz CV, Tramontozzi PJ, Vermilya K, De Rienzo A, Crucitta S, Bassères DS, Weetall M, Branstrom A, Giorgetti A, Ciampi R, Del Re M, Danesi R, Bizzarri R, Yang H, Kocher O, Klein AM, Welner RS, Bueno R, Magli MC, Clohessy JG, Ali A, Tenen DG, Levantini E. Maroni G, et al. Among authors: crucitta s. Commun Biol. 2021 Apr 14;4(1):370. doi: 10.1038/s42003-021-01897-6. Commun Biol. 2021. PMID: 33854168 Free PMC article.
Circulating biomarkers of response to immunotherapy in cancer treatment.
Del Re M, Gianfilippo G, Crucitta S, Addeo A, van Schaik RH, Danesi R. Del Re M, et al. Among authors: crucitta s. Pharmacogenomics. 2019 Dec;20(18):1247-1249. doi: 10.2217/pgs-2019-0117. Epub 2019 Nov 6. Pharmacogenomics. 2019. PMID: 31691637 No abstract available.
Clinical utility of Next Generation Sequencing of plasma cell-free DNA for the molecular profiling of patients with NSCLC at diagnosis and disease progression.
Del Re M, Luculli GI, Petrini I, Sbrana A, Scotti V, Perez DM, Livi L, Crucitta S, Iannopollo M, Mazzoni F, Ruglioni M, Tibaldi C, Olmetto E, Stasi I, Baldini E, Allegrini G, Antonuzzo L, Morelli F, Pierini A, Panzeri N, Fogli S, Chella A, Rolfo C, Danesi R. Del Re M, et al. Among authors: crucitta s. Transl Oncol. 2024 Mar;41:101869. doi: 10.1016/j.tranon.2023.101869. Epub 2024 Jan 29. Transl Oncol. 2024. PMID: 38290249 Free PMC article.
erbB in NSCLC as a molecular target: current evidences and future directions.
Del Re M, Cucchiara F, Petrini I, Fogli S, Passaro A, Crucitta S, Attili I, De Marinis F, Chella A, Danesi R. Del Re M, et al. Among authors: crucitta s. ESMO Open. 2020 Aug;5(4):e000724. doi: 10.1136/esmoopen-2020-000724. ESMO Open. 2020. PMID: 32820012 Free PMC article. Review.
67 results